StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
22
This month
1
This year
1
Publishing Date
2024 - 04 - 10
1
2023 - 10 - 31
1
2023 - 08 - 28
1
2023 - 03 - 06
1
2022 - 09 - 26
1
2022 - 09 - 06
1
2022 - 05 - 19
1
2022 - 05 - 04
1
2022 - 02 - 24
1
2022 - 02 - 09
1
2022 - 01 - 24
1
2021 - 10 - 21
2
2021 - 09 - 30
1
2021 - 08 - 31
2
2021 - 08 - 20
1
2021 - 08 - 10
1
2021 - 01 - 11
1
2020 - 12 - 17
1
2020 - 12 - 10
1
2020 - 12 - 04
1
Sector
Health technology
22
Tags
Ad04
4
Alcohol
3
Alcohol use disorder
5
Alliances
1
Als
3
Biocapital
1
Biomarkers
1
Clinical-trials-phase-iii
2
Collaboration
2
Conference
1
Diabetes
1
Drug
3
Enroll
4
For
1
Genetic
1
International
1
Medical
2
N/a
15
Nash
1
Opioid
4
Order
2
Patent
3
Pharmaceuticals
5
Phase 3
6
Pnv-5030
1
Pnv-5032
1
Pnv-6005
1
Positive
5
Potential
7
Pre-clinical
2
Preclinical
2
Product-news
1
Publication
1
Research
5
Serotonin-3
1
Therapy
1
Treatment
18
Trial
7
Ulcerative colitis
1
Update
1
Entities
Adial pharmaceuticals, inc
22
Symbols
ABBV
121
ABT
61
ADIL
22
ALNY
38
ALPMF
51
ALPMY
51
AMGN
47
ARAY
21
ARQT
25
ARWR
21
AZN
52
AZNCF
44
BBIO
20
BHC
36
BIIB
42
BMY
94
BSX
21
BTAI
20
BWAY
41
CHRS
28
CNSP
26
ECL
47
FBIO
27
FNCTF
87
GILD
50
GLAXF
78
GSK
102
HOTH
24
INCY
77
JNJ
210
KPTI
33
LLY
180
MBRX
28
MDT
46
MMM
21
MNOV
24
MRK
66
NTLA
32
NVO
37
NVS
144
NVSEF
120
PFE
75
PHG
21
PRGO
22
RARE
25
REGN
57
RETA
28
RGNX
25
SNY
295
SNYNF
247
SRNE
37
TAK
54
TEVJF
79
TFX
21
TGTX
24
TNXP
32
VRCA
23
VRTX
27
VTRS
46
XYL
35
Exchanges
Nasdaq
22
Crawled Date
2024 - 04 - 10
1
2023 - 10 - 31
1
2023 - 08 - 28
1
2023 - 03 - 06
1
2022 - 09 - 26
1
2022 - 09 - 06
1
2022 - 05 - 19
1
2022 - 05 - 04
1
2022 - 02 - 24
1
2022 - 02 - 09
1
2022 - 01 - 24
1
2021 - 10 - 21
2
2021 - 09 - 30
1
2021 - 08 - 31
2
2021 - 08 - 20
1
2021 - 08 - 10
1
2021 - 01 - 11
1
2020 - 12 - 17
1
2020 - 12 - 10
1
2020 - 12 - 04
1
Crawled Time
12:30
2
13:00
2
13:20
1
14:00
5
14:15
1
14:30
2
15:00
2
15:15
1
16:00
3
17:00
2
21:00
1
Source
adialpharma.com
1
www.biospace.com
7
www.globenewswire.com
14
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
symbols :
Adil
save search
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published:
2024-04-10
(Crawled : 12:30)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
65.22%
|
O:
123.48%
H:
0.0%
C:
0.0%
ad04
alcohol
publication
treatment
pharmaceuticals
for
trial
potential
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
Published:
2023-10-31
(Crawled : 13:00)
- adialpharma.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-2.56%
|
O:
2.56%
H:
4.25%
C:
-3.5%
conference
international
pharmaceuticals
medical
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism
Published:
2023-08-28
(Crawled : 12:30)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-44.61%
|
O:
0.29%
H:
0.0%
C:
-2.91%
alcohol
pharmaceuticals
research
medical
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
Published:
2023-03-06
(Crawled : 21:00)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
352.38%
|
O:
40.95%
H:
1.35%
C:
-25.19%
ad04
treatment
alcohol
pharmaceuticals
update
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic PainPNV-5030 significantly reduced pain compared to both placebo and acetaminophen
Published:
2022-09-26
(Crawled : 14:00)
- biospace.com/
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
405.59%
|
O:
-0.35%
H:
6.28%
C:
3.18%
pnv-5030
treatment
pharmaceuticals
potential
positive
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis
Published:
2022-09-06
(Crawled : 13:00)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
274.09%
|
O:
8.33%
H:
7.23%
C:
-7.12%
pnv-6005
treatment
potential
positive
ulcerative colitis
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH
Published:
2022-05-19
(Crawled : 14:00)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
39.71%
|
O:
0.74%
H:
3.28%
C:
0.0%
research
collaboration
diabetes
potential
nash
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
Published:
2022-05-04
(Crawled : 13:20)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
31.03%
|
O:
0.69%
H:
0.0%
C:
-4.79%
research
collaboration
potential
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
Published:
2022-02-24
(Crawled : 14:30)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-5.0%
|
O:
0.0%
H:
9.0%
C:
9.0%
ad04
alcohol use disorder
treatment
als
order
trial
phase 3
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma
Published:
2022-02-09
(Crawled : 14:30)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-20.83%
|
O:
7.92%
H:
1.16%
C:
-5.79%
pnv-5032
treatment
als
potential
positive
Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04Patent covers patients with a specific genetic biomarker for the serotonin-3 receptor
Published:
2022-01-24
(Crawled : 15:00)
- biospace.com/
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-18.8%
|
O:
-3.42%
H:
4.87%
C:
3.98%
ad04
treatment
genetic
als
serotonin-3
order
patent
opioid
biomarkers
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as a Drug Candidate for the Treatment of Pain
Published:
2021-10-21
(Crawled : 15:15)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-54.55%
|
O:
-0.24%
H:
11.51%
C:
-7.67%
treatment
pre-clinical
positive
drug
preclinical
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as Drug Candidate for the Treatment of Pain
Published:
2021-10-21
(Crawled : 14:15)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-54.55%
|
O:
-0.24%
H:
11.51%
C:
-7.67%
treatment
pre-clinical
positive
drug
preclinical
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
Published:
2021-09-30
(Crawled : 14:00)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-54.55%
|
O:
0.48%
H:
3.57%
C:
2.14%
alcohol use disorder
treatment
phase 3
trial
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderONWARD trial enrollment closed; trial completion expected in Q1 2022
Published:
2021-08-31
(Crawled : 17:00)
- biospace.com/
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-54.0%
|
O:
2.54%
H:
3.19%
C:
-3.19%
alcohol use disorder
treatment
phase 3
trial
enroll
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
Published:
2021-08-31
(Crawled : 14:00)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-54.0%
|
O:
2.54%
H:
3.19%
C:
-3.19%
alcohol use disorder
treatment
phase 3
trial
enroll
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
Published:
2021-08-20
(Crawled : 15:00)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-39.1%
|
O:
0.32%
H:
11.82%
C:
6.71%
alcohol use disorder
treatment
phase 3
trial
enroll
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
Published:
2021-08-10
(Crawled : 14:00)
- globenewswire.com
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-30.66%
|
O:
0.36%
H:
6.18%
C:
-0.73%
treatment
opioid
patent
Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder
Published:
2021-01-11
(Crawled : 16:00)
- biospace.com/
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-1.55%
|
O:
0.0%
H:
10.36%
C:
7.25%
patent
opioid
treatment
Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder
Published:
2020-12-17
(Crawled : 17:00)
- biospace.com/
ADIL
|
News
|
$1.895
-1.81%
-1.85%
2.5M
|
Health Technology
|
-1.04%
|
O:
0.52%
H:
3.11%
C:
-2.59%
phase 3
trial
treatment
enroll
← Previous
1
2
Next →
Gainers vs Losers
75%
25%
Top 10 Gainers
MTTR
|
News
M
|
$4.78
174.71%
63.6%
72M
|
AGBA
|
$2.565
105.2%
51.27%
200M
|
Finance
MLEC
|
$2.44
74.29%
42.62%
78M
|
n/a
EDBL
|
News
|
$6.28
67.02%
40.13%
16M
|
ATGL
|
$2.91
48.81%
32.8%
180K
|
ZAPP
|
$0.2175
47.16%
32.05%
16M
|
n/a
ONFO
|
$0.6075
38.38%
27.74%
7.3M
|
n/a
VIVK
|
$1.48
38.32%
27.7%
530K
|
Professional, Scientific, and T...
MNTS
|
$0.5
35.69%
26.3%
4.8M
|
SDIG
A
|
$3.635
35.13%
26.0%
1M
|
Your saved searches
Save your searches and get alerts when important news are released.